RxDoctor Payments DataLook up a doctor →

David Ettinger

Medical · Corpus Christi, TXNPI 1598096018

Payments from drug & device makers

$15,570in general payments, 2019–2025

Across 868 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Sanofi$1K
  • Novartis$1K
  • UCB, Inc.$906
  • Sun Pharmaceutical Industries Inc.$899
  • plus $7K from 23 others

What the payments were for

  • Consulting fees$2502%
  • Food & beverage$15,15097%
  • Education$1701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,570 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$245,539
Medicare patients
1,026
Services billed
5,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab38$149,897
OtezlaApremilast12$57,891
Dupixent SyringeDupilumab11$48,332
Clobetasol Propionate142$6,692
Tacrolimus29$4,396
Fluorouracil55$3,463
Ketoconazole154$3,213
Pimecrolimus14$2,828
Triamcinolone Acetonide225$2,579
Metronidazole53$2,231
Clindamycin Phosphate52$1,828
Tretinoin26$1,806
Doxycycline Monohydrate80$1,767
Calcipotriene13$1,618
Doxycycline Hyclate62$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$371$57,89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.

Other medical in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →